FDA Approves Groundbreaking Cell Therapy for Type 1 Diabetes

The FDA has approved Lantidra, a cellular therapy made from deceased donor pancreatic cells, to help adults with Type 1 diabetes maintain their target blood glucose levels. Lantidra aims to replace the insulin-producing beta cells in the pancreas, potentially eliminating the need for daily injections or infusions of insulin. Clinical studies have shown that a significant number of participants did not need insulin for one to five years or more after receiving Lantidra infusions. However, there were some side effects and serious adverse reactions reported, so patients are advised to discuss the benefits and risks with their doctors.